This review uncovers the role of innate lymphoid cells in mucosal remodeling in chronic rhinosinusitis with nasal polyps, implying new treatment strategies.
Key Points
This review aims to explore the role of innate lymphoid cells in chronic rhinosinusitis with nasal polyps and the effects of IL-4Rα blockade via dupilumab.
Synthesis of current knowledge on ILC classification and plasticity
Analysis of ILC progenitor biology
Review of epithelial–ILC communication and its implications
Integration of clinical and translational studies on ILC2 phenotypes and treatment predictions.
ILC2s are central to type 2 inflammation associated with chronic rhinosinusitis.
Dupilumab reduces ILC2 functions and restores epithelial integrity.
Baseline ILC2 phenotypes may predict response to dupilumab treatment.
ILC profiling could serve as a promising biomarker strategy.